Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Noroxin Efficacy and Safety Trial
NCT03506256Phase 4
Key facts
- Status
- Unknown
- Start
- May 2018
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Drugs
- norfloxacin
- Conditions
- urinary tract infection (UTI)
01
Overview
Phase 4, open-label, single-arm trial of norfloxacin in urinary tract infection (UTI). Primary endpoint: Number of Patients treated with Noroxin (Efficacy) at 14 days. Status: unknown.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Norofloxacin
Norfloxacin 400 MG
03
Who it enrols
Adult patients with at least one typical symptom of acute, lower urinary tract infection. Patients with diabetes, immunosuppression, pregnancy, or recurrent UTIs are excluded.
04
Endpoints
Primary
Number of Patients treated with Noroxin (Efficacy)
Secondary
Number of Adverse Effects with Noroxin (Safety)
Beyond the preview
Go deeper on NCT03506256.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03506256.